Physician profile
Jon Soble
NPI 1487639969
$5,159.00
in general payments reported to CMS, 2019-2025
30 companies · $573 in 2025
The $573 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $638 · 2020: $698 · 2021: $2,439 · 2022: $701 · 2023: $109 · 2025: $573.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $573 · Food and Beverage: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $573.36 |
| Food and Beverage | $109.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $967.03 | 2019-2022 | |
| Olympus Corporation of The Americas | $573.36 | 2025 | Gyrus Acmi, Uretero-Reno Fiberscope, Uropass |
| Boston Scientific Corporation | $474.78 | 2019-2023 | Lithovue, Spaceoar Vue System - 10ml |
| Janssen Biotech, INC. | $431.01 | 2019-2022 | |
| Endo Pharmaceuticals INC. | $294.78 | 2019-2022 | |
| Abbvie INC. | $273.07 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $261.41 | 2019-2022 | |
| Amgen INC. | $255.46 | 2020-2022 | |
| Coloplast Corp | $217.56 | 2021-2022 | |
| C. R. Bard, INC. & Subsidiaries | $172.48 | 2019 | |
| Pfizer INC. | $164.19 | 2020-2022 | |
| Allergan, INC. | $152.51 | 2021-2022 | |
| Myriad Genetic Laboratories, INC. | $137.98 | 2021-2022 | |
| Tolmar Pharmaceuticals, INC. | $132.74 | 2019-2022 | |
| Dendreon Pharmaceuticals LLC | $113.66 | 2019-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $78.87 | 2020-2021 | |
| Urovant Sciences INC | $63.17 | 2021-2022 | |
| Clarus Therapeutics INC. | $58.92 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $47.54 | 2020-2021 | |
| Karl Storz Endoscopy-America | $46.84 | 2021 | |
| Blue Earth Diagnostics | $42.48 | 2021 | |
| Urogen Pharma, INC. | $32.59 | 2020-2021 | |
| Metuchen Pharmaceuticals | $29.35 | 2020 | |
| Myovant Sciences INC. | $25.87 | 2021 | |
| Cook Medical LLC | $24.54 | 2021-2022 | |
| Travere Therapeutics, INC. | $24.13 | 2019 | |
| Ethicon US, LLC | $19.24 | 2019 | |
| Tersera Therapeutics LLC | $17.05 | 2019 | |
| Convatec INC. | $13.24 | 2019 | |
| Medtronic USA, INC. | $13.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Soble listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.